AARD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aardvark Therapeutics Inc (AARD) is not a good buy for a beginner investor with a long-term strategy. The stock is facing significant uncertainty due to the voluntary pause of its Phase 3 HERO trial, legal investigations, and consistent downgrades from analysts. Additionally, technical indicators are bearish, and there are no strong positive catalysts to offset the risks. It is recommended to avoid this stock at this time.
The technical indicators are bearish. The MACD histogram is negative and contracting, RSI is neutral at 22.403, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 4.909 and S2 at 4.508. The overall trend suggests further downside potential.
The company has highlighted the potential of ARD-101 in Prader-Willi syndrome and obesity, with a $1B+ addressable market in the U.S. Clean safety was observed at therapeutic doses, which may allow a path forward for the drug.
The voluntary pause of the Phase 3 HERO trial due to reversible cardiac observations has raised significant concerns. Legal investigations into potential securities fraud and class action lawsuits add further uncertainty. Analysts have downgraded the stock significantly, with price targets cut drastically. The company's financials show no revenue and significant losses, and there are no recent insider or hedge fund buying trends.
In 2025/Q3, the company reported no revenue growth, a net income loss of -$16.32M (up 290.15% YoY), and an EPS of -0.75 (up 275% YoY). While the YoY improvement in net income and EPS is notable, the company remains unprofitable with no revenue generation.
Analysts have downgraded the stock significantly following the trial pause. Oppenheimer, BTIG, Cantor Fitzgerald, Morgan Stanley, RBC Capital, H.C. Wainwright, and Stifel have all lowered price targets and ratings. The consensus reflects increased risk and uncertainty in the near term, with price targets now ranging from $6 to $9, down from previous highs of $18 to $50.
